Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1060
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorGIGANTE, Alexandre Duarte-
dc.contributor.authorBOND, David J.-
dc.contributor.authorLAFER, Beny-
dc.contributor.authorLAM, Raymond W.-
dc.contributor.authorYOUNG, L. Trevor-
dc.contributor.authorYATHAM, Lakshmi N.-
dc.date.accessioned2013-07-30T15:18:50Z-
dc.date.available2013-07-30T15:18:50Z-
dc.date.issued2012-
dc.identifier.citationBIPOLAR DISORDERS, v.14, n.5, p.478-487, 2012-
dc.identifier.issn1398-5647-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1060-
dc.description.abstractGigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord 2012: 14: 478487. (c) 2012 The Authors. Journal compilation (c) 2012 John Wiley & Sons A/S. Objectives: Bipolar disorder (BD) is a common and highly disabling disease characterized by substantial cognitive and functional impairment. The exact neurobiological mechanisms underlying the expression of symptoms in this condition remain unknown but there is growing evidence that glutamate might play an important role. Using proton magnetic resonance spectroscopy (1H-MRS), a number of studies have examined brain glutamate/glutamine levels in patients with bipolar disorder, but they have produced conflicting results. The objective of this paper was to conduct a systematic review and meta-analysis of the literature on brain glutamate/glutamine in BD as measured by 1H-MRS. Methods: A Medline search for the period January 1980April 2010 was conducted to identify published studies that used 1H-MRS to measure glutamate + glutamine (Glx), the Glx/creatine (Cr) ratio, glutamate (Glu), or the Glu/Cr ratio in any brain region in adult or child/adolescent patients with BD and healthy subjects. A meta-analysis of the pooled data was conducted. Results: BD patients were found to have increased Glx compared to healthy subjects when all brain areas were combined. This finding remained true in medicated and non-medicated patients, and in frontal brain areas in adults. There was a non-significant trend (p = 0.09) for an increase in whole-brain Glx/Cr and Glu in patients compared with healthy subjects. No significant difference was found in Glu/Cr. Conclusions: The results of this meta-analysis suggest that brain Glx levels are elevated in BD patients and support the idea that glutamate might play an important role in the pathophysiology of BD.-
dc.description.sponsorshipUniversity of Oeste Paulista (UNOESTE), Presidente Prudente, Sao Paulo, Brazil-
dc.description.sponsorshipDepartment of Psychiatry, University of British Columbia, Vancouver, Canada-
dc.description.sponsorshipCanadian Institutes of Health Research (CIHR)-
dc.description.sponsorshipUBC Institute of Mental Health/Coast Capital Depression Research Fund-
dc.description.sponsorshipCanadian Network for Mood and Anxiety Treatments (CANMAT)-
dc.description.sponsorshipCanadian Psychiatric Association-
dc.description.sponsorshipAstraZeneca-
dc.description.sponsorshipJanssen-Ortho-
dc.description.sponsorshipBristol-Myers Squibb-
dc.description.sponsorshipOtsuka-
dc.description.sponsorshipBiovail-
dc.description.sponsorshipCanadian Institutes of Health Research-
dc.description.sponsorshipEli Lilly Co.-
dc.description.sponsorshipLitebook Company-
dc.description.sponsorshipLundbeck-
dc.description.sponsorshipLundbeck Institute-
dc.description.sponsorshipMochida-
dc.description.sponsorshipPfizer-
dc.description.sponsorshipServier-
dc.description.sponsorshipSt. Jude's Medical-
dc.description.sponsorshipTakeda-
dc.description.sponsorshipUBC Institute of Mental Health/Coast Capital Savings-
dc.description.sponsorshipForest-
dc.description.sponsorshipGlaxoSmithKline-
dc.description.sponsorshipJanssen-
dc.description.sponsorshipMichael Smith Foundation for Health Research-
dc.description.sponsorshipNovartis-
dc.description.sponsorshipRanbaxy-
dc.description.sponsorshipStanley Foundation-
dc.language.isoeng-
dc.publisherWILEY-BLACKWELL-
dc.relation.ispartofBipolar Disorders-
dc.rightsrestrictedAccess-
dc.subjectbipolar disorder-
dc.subjectglutamate-
dc.subjectglutamate plus glutamine (Glx)-
dc.subjectmeta-analysis-
dc.subjectproton magnetic resonance spectroscopy-
dc.subject.otherdorsolateral prefrontal cortex-
dc.subject.othercellular plasticity cascades-
dc.subject.otheranterior cingulate cortex-
dc.subject.otherexcitatory amino-acids-
dc.subject.otherpituitary-adrenal axis-
dc.subject.othermitochondrial dysfunction-
dc.subject.otherpsychiatric-disorders-
dc.subject.othercortical glutamate-
dc.subject.otheroxidative stress-
dc.subject.othermood disorders-
dc.titleBrain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis-
dc.typearticle-
dc.rights.holderCopyright WILEY-BLACKWELL-
dc.identifier.doi10.1111/j.1399-5618.2012.01033.x-
dc.identifier.pmid22834460-
dc.subject.wosClinical Neurology-
dc.subject.wosNeurosciences-
dc.subject.wosPsychiatry-
dc.type.categoryreview-
dc.type.versionpublishedVersion-
hcfmusp.author.externalBOND, David J.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada-
hcfmusp.author.externalLAM, Raymond W.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada-
hcfmusp.author.externalYOUNG, L. Trevor:Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada-
hcfmusp.author.externalYATHAM, Lakshmi N.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada-
hcfmusp.description.beginpage478-
hcfmusp.description.endpage487-
hcfmusp.description.issue5-
hcfmusp.description.volume14-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84864388823-
hcfmusp.origem.idWOS:000306805000003-
hcfmusp.publisher.cityHOBOKEN-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAalto S, 2005, PSYCHOPHARMACOLOGY, V182, P375, DOI 10.1007/s00213-005-0092-6-
hcfmusp.relation.referenceALTAMURA CA, 1993, AM J PSYCHIAT, V150, P1731-
hcfmusp.relation.referenceAndreazza AC, 2008, J AFFECT DISORDERS, V111, P135, DOI 10.1016/j.jad.2008.04.013-
hcfmusp.relation.referenceArnone D, 2009, BRIT J PSYCHIAT, V195, P194, DOI 10.1192/bjp.bp.108.059717-
hcfmusp.relation.referenceAtmaca M, 2009, INT REV PSYCHIATR, V21, P410, DOI 10.1080/09540260902962206-
hcfmusp.relation.referenceBarker PB, 2001, MAGNET RESON MED, V45, P765, DOI 10.1002/mrm.1104-
hcfmusp.relation.referenceBeneyto M, 2006, SYNAPSE, V60, P585, DOI 10.1002/syn.20329-
hcfmusp.relation.referenceBhagwagar Z, 2007, BIOL PSYCHIAT, V61, P806, DOI 10.1016/j.biopsych.2006.08.048-
hcfmusp.relation.referenceCarr DB, 2000, J NEUROSCI, V20, P3864-
hcfmusp.relation.referenceCastillo M, 2000, AM J NEURORADIOL, V21, P832-
hcfmusp.relation.referenceChuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x-
hcfmusp.relation.referenceClausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5-
hcfmusp.relation.referenceColla M, 2009, MOL PSYCHIATR, V14, P696, DOI 10.1038/mp.2008.26-
hcfmusp.relation.referenceCousins DA, 2009, BIPOLAR DISORD, V11, P787, DOI 10.1111/j.1399-5618.2009.00760.x-
hcfmusp.relation.referenceDaban C, 2005, PSYCHIAT CLIN N AM, V28, P469, DOI 10.1016/j.psc.2005.01.005-
hcfmusp.relation.referenceDager SR, 2004, ARCH GEN PSYCHIAT, V61, P450, DOI 10.1001/archpsyc.61.5.450-
hcfmusp.relation.referenceDavanzo P, 2001, NEUROPSYCHOPHARMACOL, V24, P359, DOI 10.1016/S0893-133X(00)00207-4-
hcfmusp.relation.referenceDavanzo P, 2003, AM J PSYCHIAT, V160, P1442, DOI 10.1176/appi.ajp.160.8.1442-
hcfmusp.relation.referenceDel Arco A, 2009, J NEURAL TRANSM, V116, P941, DOI 10.1007/s00702-009-0243-8-
hcfmusp.relation.referenceDelBello MP, 2006, NEUROPSYCHOPHARMACOL, V31, P1264, DOI 10.1038/sj.npp.1300950-
hcfmusp.relation.referenceDong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24-
hcfmusp.relation.referenceFrey BN, 2007, BIPOLAR DISORD, V9, P119, DOI 10.1111/j.1399-5618.2007.00454.x-
hcfmusp.relation.referenceFrye MA, 2007, PSYCHIAT RES-NEUROIM, V154, P259, DOI 10.1016/j.pscychresns.2006.11.003-
hcfmusp.relation.referenceFrye MA, 2007, NEUROPSYCHOPHARMACOL, V32, P2490, DOI 10.1038/sj.npp.1301387-
hcfmusp.relation.referenceGigante A. D., 2010, INT J NEUROPSYCHOPH, V23, P1-
hcfmusp.relation.referenceGonul AS, 2009, INT REV PSYCHIATR, V21, P323, DOI 10.1080/09540260902962131-
hcfmusp.relation.referenceGoodwin FK, 2007, MANIC DEPRESSIVE ILL-
hcfmusp.relation.referenceGRUETTER R, 1994, J NEUROCHEM, V63, P1377-
hcfmusp.relation.referenceHashimoto K, 2007, BIOL PSYCHIAT, V62, P1310, DOI 10.1016/j.biopsych.2007.03.017-
hcfmusp.relation.referenceHashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022-3042.2001.00728.x-
hcfmusp.relation.referenceHassel B., 2006, BASIC NEUROCHEMISTRY, P267-
hcfmusp.relation.referenceHeath PR, 2002, MUSCLE NERVE, V26, P438, DOI 10.1002/mus.10186-
hcfmusp.relation.referenceHoekstra R, 2006, EUR NEUROPSYCHOPHARM, V16, P71, DOI 10.1016/j.euroneuro.2005.06.003-
hcfmusp.relation.referenceItokawa M, 2003, NEUROSCI LETT, V345, P53, DOI 10.1016/S0304-3940(03)00501-9-
hcfmusp.relation.referenceKapczinski Flavio, 2008, Expert Rev Neurother, V8, P1101, DOI 10.1586/14737175.8.7.1101-
hcfmusp.relation.referenceKapczinski F, 2011, J PSYCHIATR RES, V45, P156, DOI [10.1016/j.jpsychires.2010.05.015, 10.1016/j.psychires.2010.05.015]-
hcfmusp.relation.referenceKato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x-
hcfmusp.relation.referenceKato T, 2008, TRENDS NEUROSCI, V31, P495, DOI 10.1016/j.tins.2008.07.007-
hcfmusp.relation.referenceKaufman RE, 2009, PROG NEURO-PSYCHOPH, V33, P427, DOI 10.1016/j.pnpbp.2008.12.025-
hcfmusp.relation.referenceKim YK, 2007, J AFFECT DISORDERS, V104, P91, DOI 10.1016/j.jad.2007.02.018-
hcfmusp.relation.referenceKristiansen LV, 2005, SCHIZOPHR RES, V78, P87, DOI 10.1016/j.schres.2005.06.012-
hcfmusp.relation.referenceMacQueen GM, 2001, ACTA PSYCHIAT SCAND, V103, P163, DOI 10.1034/j.1600-0447.2001.00059.x-
hcfmusp.relation.referenceMartinowich K, 2009, J CLIN INVEST, V119, P726, DOI 10.1172/JCI37703-
hcfmusp.relation.referenceMcCullumsmith RE, 2007, BRAIN RES, V1127, P108, DOI 10.1016/j.brainres.2006.09.011-
hcfmusp.relation.referenceMerikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543-
hcfmusp.relation.referenceMichael N, 2003, PSYCHOPHARMACOLOGY, V168, P344, DOI 10.1007/s00213-003-1440-z-
hcfmusp.relation.referenceMichael N, 2009, PSYCHIAT RES-NEUROIM, V172, P78, DOI 10.1016/j.pscychresns.2009.01.002-
hcfmusp.relation.referenceMOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x-
hcfmusp.relation.referenceMoore CM, 2007, J AM ACAD CHILD PSY, V46, P524, DOI 10.1097/chi.0b013e31802f5f2c-
hcfmusp.relation.referenceMundo E, 2003, MOL PSYCHIATR, V8, P241, DOI 10.1038/sj.mp.4001218-
hcfmusp.relation.referenceMurray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740-
hcfmusp.relation.referenceNery FG, 2010, J PSYCHIATR RES, V44, P278, DOI 10.1016/j.jpsychires.2009.09.006-
hcfmusp.relation.referenceOlvera RL, 2007, J CHILD ADOL PSYCHOP, V17, P461, DOI 10.1089/cap.2007.0102-
hcfmusp.relation.referenceOngur D, 2008, BIOL PSYCHIAT, V64, P718, DOI 10.1016/j.biopsych.2008.05.014-
hcfmusp.relation.referenceRajkowska G, 2002, BIPOLAR DISORD, V4, P105, DOI 10.1034/j.1399-5618.2002.01149.x-
hcfmusp.relation.referenceRao JS, 2007, J NEUROCHEM, V102, P1918, DOI 10.1111/j.1471-4159.2007.04648.x-
hcfmusp.relation.referenceRao JS, 2010, MOL PSYCHIATR, V15, P384, DOI 10.1038/mp.2009.47-
hcfmusp.relation.referenceRosa AR, 2010, VALUE HEALTH, V13, P984, DOI 10.1111/j.1524-4733.2010.00768.x-
hcfmusp.relation.referenceRoss B, 2001, ANAT REC, V265, P54, DOI 10.1002/ar.1058-
hcfmusp.relation.referenceSanacora G, 2008, NAT REV DRUG DISCOV, V7, P426, DOI 10.1038/nrd2462-
hcfmusp.relation.referenceSchloesser RJ, 2008, NEUROPSYCHOPHARMACOL, V33, P110, DOI 10.1038/sj.npp.1301575-
hcfmusp.relation.referenceSchmider J, 1995, BIOL PSYCHIAT, V38, P797, DOI 10.1016/0006-3223(95)00064-X-
hcfmusp.relation.referenceSchubert MI, 2008, J PSYCHIATR RES, V42, P902, DOI 10.1016/j.jpsychires.2007.10.003-
hcfmusp.relation.referenceSenaratne R, 2009, PSYCHIAT RES-NEUROIM, V172, P205, DOI 10.1016/j.pscychresns.2008.07.007-
hcfmusp.relation.referenceSesack SR, 2003, ANN NY ACAD SCI, V1003, P36, DOI 10.1196/annals.1300.066-
hcfmusp.relation.referenceShao L, 2005, BIOL PSYCHIAT, V58, P879, DOI 10.1016/j.biopsych.2005.04-052-
hcfmusp.relation.referenceSingh M, 2010, PSYCHIAT RES-NEUROIM, V182, P165, DOI 10.1016/j.pscychresns.2010.01.003-
hcfmusp.relation.referenceStork C, 2005, MOL PSYCHIATR, V10, P900, DOI 10.1038/sj.mp.4001711-
hcfmusp.relation.referenceTohen M, 2000, AM J PSYCHIAT, V157, P220, DOI 10.1176/appi.ajp.157.2.220-
hcfmusp.relation.referenceTorres IJ, 2010, J CLIN PSYCHIAT, V71, P1234, DOI 10.4088/JCP.08m04997yel-
hcfmusp.relation.referenceWang JF, 2009, BIPOLAR DISORD, V11, P523, DOI 10.1111/j.1399-5618.2009.00717.x-
hcfmusp.relation.referenceWatson S, 2004, BRIT J PSYCHIAT, V184, P496, DOI 10.1192/bjp.184.6.496-
hcfmusp.relation.referenceZarate CA, 2006, BIOL PSYCHIAT, V59, P1006, DOI 10.1016/j.biopsych.2005.10.021-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipAstraZeneca-
hcfmusp.remissive.sponsorshipBristol-Myers Squibb-
hcfmusp.remissive.sponsorshipCIHR-
hcfmusp.remissive.sponsorshipGlaxoSmithKline-
hcfmusp.remissive.sponsorshipJanssen-
hcfmusp.remissive.sponsorshipLilly-
hcfmusp.remissive.sponsorshipLundbeck-
hcfmusp.remissive.sponsorshipNovartis-
hcfmusp.remissive.sponsorshipOtsuka-
hcfmusp.remissive.sponsorshipPfizer-
hcfmusp.remissive.sponsorshipServier-
hcfmusp.remissive.sponsorshipStanley-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus126-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPS
Departamento de Psiquiatria - FM/MPS

Artigos e Materiais de Revistas Científicas - HC/IPq
Instituto de Psiquiatria - HC/IPq

Artigos e Materiais de Revistas Científicas - LIM/21
LIM/21 - Laboratório de Neuroimagem em Psiquiatria


Files in This Item:
File Description SizeFormat 
art_GIGANTE_Brain_glutamate_levels_measured_by_magnetic_resonance_spectroscopy_2012.PDF
  Restricted Access
publishedVersion (English)310.46 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.